Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
第一作者:
Kimimori,Kamijo
第一单位:
Department of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Kobe, Chuo-Ku, 650-0047, Japan. kkamijo_1107@yahoo.co.jp.
作者:
主题词
成年人(Adult);人类(Humans);白消安(Busulfan);移植物抗宿主病(Graft vs Host Disease);肿瘤复发, 局部(Neoplasm Recurrence, Local);造血干细胞移植(Hematopoietic Stem Cell Transplantation);淋巴瘤, 非霍奇金(Lymphoma, Non-Hodgkin);阿糖腺苷(Vidarabine);移植预处理(Transplantation Conditioning)
DOI
10.1007/s00277-023-05084-x
PMID
36631705
发布时间
2023-03-04
- 浏览0

Annals of hematology
651-661页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文